Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors Harboring a BRAF V600 Mutation

Interventions: Drug: LGX818
Drug: MEK162
Drug: LEE011

First Posted Date: 2012-03-05

Last Posted Date: 2024-03-13

Lead Sponsor: Pfizer

Target Recruit Count: 189

Registration Number: NCT01543698

Locations: 🇺🇸
Ophthalmic Consultants of Boston Inc (OCB), Boston, Massachusetts, United States
🇨🇭
Kantonsspital St. Gallen, St.Gallen, Switzerland
🇫🇷
Hôpital Saint louis, Paris, France

and more 21 locations

Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia

Completed

Conditions: Renal Anemia
Pregnancy
Lactation

First Posted Date: 2012-03-05

Last Posted Date: 2020-10-01

Lead Sponsor: Pfizer

Target Recruit Count: 4501

Registration Number: NCT01543477

Locations: 🇫🇮
Pietarsaari Hospital Medical clinic, Jakobstad, Finland
🇩🇰
Department of Renal Medicine Medicinerhuset 3 sal Aalborg University Hospital, Aalborg, Denmark
🇧🇬
MHAT "Dr. Tota Venkova"AD, Gabrovo, Bulgaria

and more 162 locations

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: PH-797804

First Posted Date: 2012-03-05

Last Posted Date: 2014-10-27

Lead Sponsor: Pfizer

Target Recruit Count: 730

Registration Number: NCT01543919

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Phase 3

Completed

Conditions: Meningococcal Infection

Interventions: Procedure: blood sampling
Drug: bivalent rLP2086

First Posted Date: 2012-03-02

Last Posted Date: 2020-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 698

Registration Number: NCT01543087

Locations: 🇺🇸
Dr. Shelly David Senders MD Inc. dba Senders Pediatrics, Cleveland, Ohio, United States
🇫🇮
Tampere Vaccine Research Clinic, Tampere, Finland
🇺🇸
Clinical Research Advantage, Inc./ East Valley Family Physicians, PLC, Chandler, Arizona, United States

and more 43 locations

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-05175157
Drug: Placebo

First Posted Date: 2012-02-23

Last Posted Date: 2012-07-10

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT01537497

Locations: 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States

CP-751,871 Treatment For Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: CP-751,871

First Posted Date: 2012-02-20

Last Posted Date: 2013-03-15

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT01536145

Locations: 🇺🇸
Pfizer Investigational Site, New York, New York, United States

A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CAZ-AVI
Drug: metronidazole
Drug: CAZ-AVI + metronidazole

First Posted Date: 2012-02-16

Last Posted Date: 2017-09-05

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT01534247

Locations: 🇺🇸
Research site, Overland Park, Kansas, United States

A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

Phase 1

Completed

Conditions: Analgesia
Acute Pain
Chronic Pain
Narcotic Abuse
Opioid-related Disorders

Interventions: Drug: marketed oxycodone hydrochloride
Drug: oxycodone hydrochloride

First Posted Date: 2012-02-10

Last Posted Date: 2012-02-24

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT01530542

Locations: 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States

A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-05180999

First Posted Date: 2012-02-10

Last Posted Date: 2012-05-01

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01530529

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Pneumococcal Infection

Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine

First Posted Date: 2012-02-10

Last Posted Date: 2018-09-07

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT01531322

Locations: 🇨🇳
Pfizer Investigational Site, Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy